Skip to main content
Journal cover image

A phase II study of docetaxel-irinotecan combination in advanced pancreatic cancer.

Publication ,  Journal Article
Kurtz, J-E; Négrier, S; Husseini, F; Limacher, J-M; Borel, C; Wagner, J-P; Prévot, G; Bergerat, J-P; Dufour, P
Published in: Hepatogastroenterology
2003

BACKGROUND/AIMS: Chemotherapy provides dismal results in advanced pancreatic cancer patients, even when new compounds, such as gemcitabine, are used. Phase I studies of single-drug therapy with docetaxel or irinotecan suggested a response rate of about 15% in these patients. We report here a phase II study of docetaxel-irinotecan combination in advanced pancreatic cancer patients. METHODOLOGY: Docetaxel 60 mg/m2 was given in combination with irinotecan 250 mg/m2 every 3 weeks. Prednisolone premedication and anti-HT3 drugs were systematically administered. Hematopoietic growth factors were given in case of febrile neutropenia or grade 4 neutropenia at the previous cycle. Endpoints were response rate, progression-free survival, and tolerance. RESULTS: Twenty-seven patients were enrolled, of whom 25 had metastatic disease. We observed 3 partial responses and 11 stabilizations. The median progression-free survival was 4.3 months. Myelosuppression was the main toxicity with 18% of patients experiencing a grade 3-4 event. One patient died of neglected febrile neutropenia. Gastrointestinal toxicity was well controlled. Other toxicities were mild. CONCLUSIONS: This combination has acceptable tolerance and, despite an 11% response rate, some partial responses and prolonged stabilizations were observed. The treatment induced clinical benefit in 33% of the patients. Further trials should focus on docetaxel or irinotecan, possibly used in combination with more conventional strategies (gemcitabine).

Duke Scholars

Published In

Hepatogastroenterology

ISSN

0172-6390

Publication Date

2003

Volume

50

Issue

50

Start / End Page

567 / 570

Location

Greece

Related Subject Headings

  • Taxoids
  • Pancreatic Neoplasms
  • Paclitaxel
  • Middle Aged
  • Liver Neoplasms
  • Irinotecan
  • Humans
  • Gastroenterology & Hepatology
  • Docetaxel
  • Diarrhea
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Kurtz, J.-E., Négrier, S., Husseini, F., Limacher, J.-M., Borel, C., Wagner, J.-P., … Dufour, P. (2003). A phase II study of docetaxel-irinotecan combination in advanced pancreatic cancer. Hepatogastroenterology, 50(50), 567–570.
Kurtz, Jean-Emmanuel, Sylvie Négrier, Fares Husseini, Jean-Marc Limacher, Christian Borel, Jean-Philippe Wagner, Gilles Prévot, Jean-Pierre Bergerat, and Patrick Dufour. “A phase II study of docetaxel-irinotecan combination in advanced pancreatic cancer.Hepatogastroenterology 50, no. 50 (2003): 567–70.
Kurtz J-E, Négrier S, Husseini F, Limacher J-M, Borel C, Wagner J-P, et al. A phase II study of docetaxel-irinotecan combination in advanced pancreatic cancer. Hepatogastroenterology. 2003;50(50):567–70.
Kurtz, Jean-Emmanuel, et al. “A phase II study of docetaxel-irinotecan combination in advanced pancreatic cancer.Hepatogastroenterology, vol. 50, no. 50, 2003, pp. 567–70.
Kurtz J-E, Négrier S, Husseini F, Limacher J-M, Borel C, Wagner J-P, Prévot G, Bergerat J-P, Dufour P. A phase II study of docetaxel-irinotecan combination in advanced pancreatic cancer. Hepatogastroenterology. 2003;50(50):567–570.
Journal cover image

Published In

Hepatogastroenterology

ISSN

0172-6390

Publication Date

2003

Volume

50

Issue

50

Start / End Page

567 / 570

Location

Greece

Related Subject Headings

  • Taxoids
  • Pancreatic Neoplasms
  • Paclitaxel
  • Middle Aged
  • Liver Neoplasms
  • Irinotecan
  • Humans
  • Gastroenterology & Hepatology
  • Docetaxel
  • Diarrhea